Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 628 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Snack Ideas and Tips for Better Sleep November 20, 2020 SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer October 24, 2023 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 EMA Starts Review of Rucaparib May 19, 2022 Load more HOT NEWS NCI-MATCH Update: More Labs, New Arms, and Initial Findings Home Is Where the Heart Is Liquid Biopsies on the Horizon for Children with Solid Cancers Coming Full Circle on Cancer and Extrachromosomal DNA
